- POSITIVE
Annual Revenue Clinitech Laboratory Mar-2026 Annual Revenue is Rs 10 Cr which is growth of 14.2% YoY.
- POSITIVE
Annual Net Profit Clinitech Laboratory Mar-2026 Annual Net Profit is Rs 0 Cr which is growth of 7.0% YoY.
BSE: 544220
Clinitech Laboratory Live Share Price Today, Share Analysis and Chart
aboutClinitech Laboratory Ltd. is a provider of diagnostic and pathological testing services. The company operates a network of diagnostic centers and laboratories, primarily serving the healthcare needs of individual patients and corporate clients throug... Read More
30.00-0.85(-2.76%)
1,200
BSE Volume
BSE 30 Oct, 2026 3:31 PM (IST)
Please subscribe to view forecaster data
Check Before You Buy
VIEW FULL CHECKLISTLow rank
3Positive10Negative
23.1%Pass in checklist
Check P/E Buy Sell Zone
Not enough data available
Clinitech Laboratory Stock Price Analysis
Day Price Range-2.8% 1 Day return | 30 (LTP) 3030 LowHigh |
|---|---|
Week Price Range-6.2% 1 Week return | 30 (LTP) 3030.8 LowHigh |
Month Price Range-10.8% 1 Month return | 30 (LTP) 3032 LowHigh |
52 Week Price Range-29.4% 1 Year return | 30 (LTP) 28.647.2 LowHigh |
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Clinitech Laboratory annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
| Indicator | Graph | CAGR 3 Yrs | CAGR 5 Yrs | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 |
|---|---|---|---|---|---|---|---|---|---|
14.9% | 16.1% | 9.7 | 8.5 | 6.4 | 6.4 | 6.5 | 4.6 | ||
Operating Exp. Ann. | 19.3% | 18.1% | 8.5 | 7.4 | 5.4 | 5 | 5.3 | 3.7 | |
Operating Profit Ann. | -10.6% | 4.6% | 1 | 0.8 | 1 | 1.4 | 1.1 | 0.8 | |
OPM Ann. % | -21.4% | -10.5% | 10.30% | 9.83% | 15.23% | 21.23% | 16.52% | 17.93% | |
18.3% | 17.3% | 9.1 | 7.9 | 5.9 | 5.5 | 5.8 | 4.1 | ||
EBITDA Ann. | -5% | 5.9% | 1.2 | 1.1 | 1 | 1.4 | 1.1 | 0.9 | |
EBITDA Ann. margin % | -17.1% | -8.3% | 12.25% | 12.52% | 15.79% | 21.48% | 17.64% | 18.85% | |
Interest Ann. | 0% | 0% | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |
Depr. | 0% | 10.8% | 0.5 | 0.5 | 0.4 | 0.5 | 0.4 | 0.3 | |
PBT Ann. | -12.6% | 0% | 0.6 | 0.6 | 0.5 | 0.9 | 0.7 | 0.6 | |
Tax Ann. | -12.6% | 14.9% | 0.2 | 0.2 | 0.1 | 0.3 | 0.2 | 0.1 | |
-12.6% | 0% | 0.4 | 0.4 | 0.4 | 0.6 | 0.5 | 0.4 | ||
Net Profit Ann. | -12.6% | 0% | 0.4 | 0.4 | 0.4 | 0.6 | 0.5 | 0.4 | |
NPM Ann. % | -22.7% | -12.8% | 4.45% | 4.79% | 5.79% | 9.65% | 8.02% | 8.83% | |
EPS Adj. latest Ann. | -11.1% | 1.1% | 1.9 | 1.7 | 1.6 | 2.7 | 2.3 | 1.8 |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Total Rev. Ann.
1Y CHG
14.1%
2Y CAGR
23.1%
3Y CAGR
14.9%
5Y CAGR
16.1%
Total Revenue Annual growth is lower than historical averages.
Net Profit Ann.
3Y CAGR
-12.6%
Net Profit Annual growth is higher than historical averages.
Operating Exp. Ann.
1Y CHG
14.9%
2Y CAGR
25.5%
3Y CAGR
19.3%
5Y CAGR
18.1%
Operating Expenses Annual Cr growth is lower than historical averages.
Clinitech Laboratory Technical Analysis
Clinitech Laboratory EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 32.1 |
|---|---|
| 10 Day | 34.0 |
| 12 Day | 34.6 |
| 20 Day | 36.1 |
| 26 Day | 36.8 |
|---|---|
| 50 Day | 38.2 |
| 100 Day | 40.7 |
| 200 Day | 49.9 |
Clinitech Laboratory Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 2026100.0%
Week100.0%
Month-
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Clinitech Laboratory Resistance and Support
30.00
Pivot
| First Resistance | 30 |
|---|---|
| Second Resistance | 30 |
| Third Resistance | 30 |
| First Support | 30 |
|---|---|
| Second Support | 30 |
| Third Support | 30 |
| Day RSI | 30.9 |
|---|---|
| Day MACD | -2.2 |
| Day MFI | 18.4 |
| Day MACD Signal Line | -1.2 |
Clinitech Laboratory Beta
| 1 Month | 2.1 |
|---|---|
| 1 Year | 0.3 |
| 3 Month | 0.4 |
|---|---|
| 3 Year | - |
Clinitech Laboratory Price Change Analysis
↓-10.9%
Over 1 Month
LowHigh
3032
↓-25%
Over 3 Months
LowHigh
3040
↓-25%
Over 6 Months
LowHigh
3045.6
↓-29.4%
Over 1 Year
LowHigh
28.647.2
Clinitech Laboratory Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| VORTON OPPORTUNITIES FUND | Bulk | Purchase | 16 Apr 2026 | 44.52 | 14,400 | BSE |
| SIDDHARTH BIPINBHAI MEHTA | Bulk | Purchase | 23 Mar 2026 | 33.20 | 12,000 | BSE |
| BINABEN BIPINKUMAR MEHTA | Bulk | Sell | 23 Mar 2026 | 33.20 | 12,000 | BSE |
| MUKESH KESHUBHAI THUMAR | Bulk | Sell | 23 Mar 2026 | 32.95 | 16,800 | BSE |
| SANJAY HARSHADRAI MEHTA | Bulk | Sell | 17 Mar 2026 | 33.34 | 18,000 | BSE |
| SANJAY HARSHADRAI MEHTA | Bulk | Purchase | 29 Jan 2026 | 32.32 | 15,600 | BSE |
| RAHUL R MAHAJAN | Bulk | Sell | 29 Jan 2026 | 29.54 | 12,000 | BSE |
| BINABEN BIPINKUMAR MEHTA | Bulk | Purchase | 17 Nov 2025 | 40.15 | 13,200 | BSE |
| BONANZA PORTFOLIO LIMITED | Bulk | Purchase | 19 Aug 2025 | 52.92 | 16,800 | BSE |
| BONANZA PORTFOLIO LIMITED | Bulk | Sell | 19 Aug 2025 | 52.97 | 3,600 | BSE |
Clinitech Laboratory Corporate Actions
Clinitech Laboratory Board Meetings
Clinitech Laboratory past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
117 Aug 2026 | Others | - |
228 May 2026 | Audited Results | - |
322 Nov 2025 | Others | Inter alia, to consider and approve formation of Subsidiary in the name & style as Medicarenx Multispeciality Hospital Private Limited and subscribe the memorandum |
412 Nov 2025 | Half Yearly Results | - |
519 Aug 2025 | Others | Inter-alia, to consider 1. Appointment of director retiring by rotation. 2. Notice convening 15th AGM and the date, time & venue thereof. 3. Other business matters. |
Clinitech Laboratory Corporate Filings
Clinitech Laboratory BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 22 Oct 2026 | Clinitech Laboratory Ltd - 544220 - Non-Applicability Of Regulation 23 Of SEBI (LODR) Regulations, 2015 W.R.T Related Party Transactions | Undertaking of non-applicability of REgulation 23 of SEBI (LODR) Regulations, 2015 w.r.t Related Party Transcations | |
| 06 Oct 2026 | Clinitech Laboratory Ltd - 544220 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 | Certificate under Reg 74(5) of SEBI (DP) Regulations for the quarter ended September 30, 2026 | |
| 26 Sep 2026 | Clinitech Laboratory Ltd - 544220 - Closure of Trading Window | Closure of Trading Window for Insiders the company from Thursday, October 01, 2026 for Unaudited Standalone & Consolidated Financial Results for thr half yera ended September 30, 2026. The Trading window will open 48 hours after declaration of said financial results | |
| 24 Sep 2026 | Clinitech Laboratory Ltd - 544220 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report | Voting Results and Scrutinizers Report for voting of AGM held on September 24, 2026 at 11.30 AM through video conferencing | |
| 24 Sep 2026 | Clinitech Laboratory Ltd - 544220 - Shareholder Meeting / Postal Ballot-Outcome of AGM | Proceedings of 16th Annual General Meeting held today i.e September 24, 2026 at 11.30 AM through video conferencing |
Clinitech Laboratory - Company Profile
Clinitech Laboratory Management Structure
Clinitech Laboratory management structure with salaries, total experience, and qualifications.
Clinitech Laboratory Board of Directors
Clinitech Laboratory Board of directors with salaries, total experience, and qualifications.
Website: www.ctllab.in
About the company - Business Profile
Clinitech Laboratory Ltd. is a provider of diagnostic and pathological testing services. The company operates a network of diagnostic centers and laboratories, primarily serving the healthcare needs of individual patients and corporate clients through a range of diagnostic investigations. It specializes in various branches of medical testing, including biochemistry, hematology, and microbiology.
Key Points
- Key Facts:
- Founded Year: 2010 (Incorporated as Clinitech Laboratory Private Limited).
- Headquarters: Navi Mumbai, Maharashtra, India.
- Stock Listing: Listed on the Bombay Stock Exchange (BSE).
- Key Personnel: Jagdish Umakant Nayak serves as the Chairman and Managing Director.
- Operations and Resources:
- The company operates through its registered office and diagnostic facilities in locations including Navi Mumbai and Dombivli.
- As of September 30, 2025, the company held property, plant, and equipment valued at ₹190.21 lakhs, and intangible assets worth ₹99.12 lakhs.
- The company maintains a focus on diagnostic laboratory testing, supported by a workforce dedicated to medical investigations.
- Market and Significance:
- Clinitech Laboratory serves the diagnostic segment of the healthcare industry, which is strategically important for early disease detection and management.
- The company provides a wide range of pathological investigations, catering to both the retail patient segment and institutional contracts.
- Business Model and Core Competencies:
- The business model is centered on providing reliable and timely diagnostic results.
- The company is skilled at managing laboratory testing workflows, as evidenced by its ₹415.89 lakhs revenue from operations in the half-year ended September 30, 2025.
- Financial Performance (Annual FY25 vs FY24):
- Revenue from Operations: The company reported ₹823.49 lakhs in FY25, compared to ₹640.30 lakhs in FY24, representing a significant year-on-year growth.
- Total Income: Stood at ₹846.26 lakhs for FY25.
- Profit After Tax (PAT): For the full year ended March 31, 2025, the company reported a PAT of ₹39.47 lakhs, up from ₹37.12 lakhs in FY24.
- Revenue Breakdown: The primary revenue stream is derived from pathological testing fees and laboratory services. For the half-year ended September 30, 2025, revenue from operations was ₹415.89 lakhs.
- Cost Structure and Employee Metrics:
- Employee Benefit Expenses: Amounted to ₹286.14 lakhs for the full year FY25.
- Laboratory Testing Charges: These reached ₹155.93 lakhs in FY25.
- Finance Costs: Reported at ₹5.51 lakhs for FY25.
- Strategic Initiatives and Future Outlook:
- The company continues to focus on enhancing its diagnostic capabilities and expanding its reach within the regional market.
- Current initiatives involve maintaining high operational standards and managing working capital efficiently, with total assets valued at ₹1112.72 lakhs as of September 2025.
References